NEUMORA THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-325.2M | — |
| FY2022 | — | $-446.9M | $240.9M |
| FY2023 | — | $469.1M | $374.0M |
| FY2024 | — | $287.1M | $142.1M |
| FY2025 | $54.5M | $103.9M | $182.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-325.2M | — |
| FY2022 | — | $-446.9M | $240.9M |
| FY2023 | — | $469.1M | $374.0M |
| FY2024 | — | $287.1M | $142.1M |
| FY2025 | $54.5M | $103.9M | $182.5M |